Literature DB >> 32022402

Hyaluronic acid-heparin conjugated decellularized human great saphenous vein patches decrease neointimal thickness.

Hualong Bai1,2, Zhiwei Wang1, Mingxing Li1, Yuanfeng Liu1, Wang Wang3,2, Peng Sun1, Shunbo Wei1, Zhiju Wang3,2, Jiang'an Li4, Alan Dardik5,6.   

Abstract

Although the science of implantable materials has advanced therapeutic options in vascular surgery, graft failure is still a problem in need of a durable solution. With the development of coating and decellularization techniques, coated prosthetic grafts have become an option; however, whether decellularized human saphenous vein can be conjugated and implanted is not known. Human great saphenous vein (GSV) was harvested and decellularized and hyaluronic acid (HA)-heparin was conjugated to the GSV; water contact angles (WCA), morphology, and sulfur element change were measured before and after heparin bonding. GSV patches were implanted into the rat inferior vena cava and aorta; patches were harvested (Day 14) and analyzed. HA-heparin was successfully conjugated to the decellularized human GSV with altered morphology and reduced WCA. The HA-heparin coated decellularized GSV patch was anti-thrombotic in vitro, and significantly decreased neointimal thickness both in patch venoplasty and angioplasty in a rat model. Both CD90 and nestin positive cells participated in neointima formation. These data show that HA-heparin coated human GSV patches decrease neointimal thickness when used both in venoplasty and arterioplasty. Tissue engineered decellularized human GSV is a promising vascular prosthesis.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  angioplasty; great saphenous vein; heparin; macrophage; patch

Year:  2020        PMID: 32022402     DOI: 10.1002/jbm.b.34574

Source DB:  PubMed          Journal:  J Biomed Mater Res B Appl Biomater        ISSN: 1552-4973            Impact factor:   3.368


  8 in total

Review 1.  Advances in Hyaluronic Acid for Biomedical Applications.

Authors:  Aqeela Yasin; Ying Ren; Jingan Li; Yulong Sheng; Chang Cao; Kun Zhang
Journal:  Front Bioeng Biotechnol       Date:  2022-07-04

2.  Delivery of rivaroxaban and chitosan rapamycin microparticle with dual antithrombosis and antiproliferation functions inhibits venous neointimal hyperplasia.

Authors:  Peng Sun; Haoliang Wu; Hao He; Liwei Zhang; Yuanfeng Liu; Cong Zhang; Chunyang Lou; Jingan Li; Hualong Bai
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

3.  Application of the Tissue-Engineered Plant Scaffold as a Vascular Patch.

Authors:  Hualong Bai; Boao Xie; Zhiwei Wang; Mingxing Li; Peng Sun; Shunbo Wei; Wang Wang; Haoliang Wu; Lei Bai; Jingan Li
Journal:  ACS Omega       Date:  2021-04-23

4.  Adventitial Progenitor Cells of Human Great Saphenous Vein Enhance the Resolution of Venous Thrombosis via Neovascularization.

Authors:  Siying Ling; Zhen Ma; Yong Teng; Xuemei Jiang; Junning Cheng; Ruihao Li; Mingyi Zhang; Hailong Luo; Yikuan Chen
Journal:  Stem Cells Int       Date:  2021-02-23       Impact factor: 5.443

5.  The application of tissue-engineered fish swim bladder vascular graft.

Authors:  Hualong Bai; Peng Sun; Haoliang Wu; Shunbo Wei; Boao Xie; Wang Wang; Yachen Hou; Jing'an Li; Alan Dardik; Zhuo Li
Journal:  Commun Biol       Date:  2021-10-05

6.  Egg Shell Membrane as an Alternative Vascular Patch for Arterial Angioplasty.

Authors:  Peng Sun; Shujie Yan; Liwei Zhang; Cong Zhang; Haoliang Wu; Shunbo Wei; Boao Xie; Xiaofeng Wang; Hualong Bai
Journal:  Front Bioeng Biotechnol       Date:  2022-03-18

7.  Wood-Derived Vascular Patches Loaded With Rapamycin Inhibit Neointimal Hyperplasia.

Authors:  Boao Xie; Liwei Zhang; Chunyang Lou; Shunbo Wei; Jing'an Li; Hualong Bai; Alan Dardik
Journal:  Front Bioeng Biotechnol       Date:  2022-07-19

8.  Programmed death-1 mediates venous neointimal hyperplasia in humans and rats.

Authors:  Peng Sun; Zhiwei Wang; Weizhen Liu; Mingxing Li; Shunbo Wei; Yanhua Xu; Zhentao Qiao; Wang Wang; Yang Fu; Hualong Bai; Jing'an Li
Journal:  Aging (Albany NY)       Date:  2021-06-24       Impact factor: 5.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.